The aim of our study was to determine the possible interrelation between muzolimine and the renal PG and renin-angiotensin systems by direct assay of these renal hormones. 4 groups of five rats were subdivided as follows: Group 1: controls Group 2: rats treated with muzolimine (100 mg/kg) Group 3: rats treated with indomethacin (4 mg/kg) Group 4: rats treated with both muzolimine and indomethacin. After 3 days, the rats were transferred to metabolic cages, urine and plasma samples were taken on the 4th day and the following parameters assayed: Urine: creatinine, Na+, PGE2. Plasma: PRA and aldosterone. Results and conclusions: Muzolimine: 1) increase PRA (11.8 ± 1.06 vs. 8.66 ± 1.56 Al ng/ml/h - p < 0.01) and 2) increases PGE2 release (7.08 ± 3.22 vs. 0.6 ± 0.19 μg/mg urine creatinine - p < 0.005). PG synthesis-inhibition (indomethacin) lowers (0.118 ± 0.056 mmol Na+/mg urine creatinine of group 2 vs 0.043 ± 0.019 mmol Na+/mg urine creatinine of group 4 - p < 0.025) although not completely abolishes (0.043 ± 0.019 nmol Na+/mg urine creatinine of group 4 vs. 0.019 ± 0.006 mmol Na+/mg of group 3 - p < 0.05) the natriuretic effect of muzolimine. This suggests that the natriuretic activity of the drug, at least in part, depends on PGE2 production.
Interaction between Muzolimine, PGE2 and the renin- angiotensin -aldosterone system
CALO', LORENZOWriting – Review & Editing
;PICCOLI A;
1985
Abstract
The aim of our study was to determine the possible interrelation between muzolimine and the renal PG and renin-angiotensin systems by direct assay of these renal hormones. 4 groups of five rats were subdivided as follows: Group 1: controls Group 2: rats treated with muzolimine (100 mg/kg) Group 3: rats treated with indomethacin (4 mg/kg) Group 4: rats treated with both muzolimine and indomethacin. After 3 days, the rats were transferred to metabolic cages, urine and plasma samples were taken on the 4th day and the following parameters assayed: Urine: creatinine, Na+, PGE2. Plasma: PRA and aldosterone. Results and conclusions: Muzolimine: 1) increase PRA (11.8 ± 1.06 vs. 8.66 ± 1.56 Al ng/ml/h - p < 0.01) and 2) increases PGE2 release (7.08 ± 3.22 vs. 0.6 ± 0.19 μg/mg urine creatinine - p < 0.005). PG synthesis-inhibition (indomethacin) lowers (0.118 ± 0.056 mmol Na+/mg urine creatinine of group 2 vs 0.043 ± 0.019 mmol Na+/mg urine creatinine of group 4 - p < 0.025) although not completely abolishes (0.043 ± 0.019 nmol Na+/mg urine creatinine of group 4 vs. 0.019 ± 0.006 mmol Na+/mg of group 3 - p < 0.05) the natriuretic effect of muzolimine. This suggests that the natriuretic activity of the drug, at least in part, depends on PGE2 production.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
